HR-CRT in Heart Failure Patients
Research type
Research Study
Full title
Haemodynamic Response to Cardiac Resynchronization Therapy in Heart Failure
IRAS ID
229436
Contact name
Timothy Rainer
Contact email
Sponsor organisation
Cardiff University
Duration of Study in the UK
0 years, 4 months, 1 days
Research summary
Heart failure (HF) is where the heart fails to pump enough blood to meet the needs of organs. It may result from any structural or functional disease impairing the heart’s ability to fill with or eject blood.
HF affects 2-3% of the population and its prevalence is increasing. Recent treatment advances have improved the outlook for sufferers, but nearly half still die within 5 years of diagnosis.
Managing HF requires a team of skilled health care professionals. We want to improve survival and quality of life, and prevent disease progression. For this we use drugs and mechanical devices. Cardiac resynchronization therapy (CRT) is one of the most exciting recent advancements in HF treatment. It targets ventricular dyssynchrony, where the heart does not beat in a coordinated way, affecting up to one third of patients with symptomatic HF. CRT improves the coordination of the heart beat and significantly improves symptoms and lifespan in many patients. However, even with careful selection up to one third of CRT patients do not respond to treatment.
Currently, evaluation of whether patients have responded well to CRT involves a time-consuming heart scan called an echocardiogram, requiring a skilled technician.
We want to investigate whether advanced physiology using a novel, non-invasive and user-friendly ultrasound device called USCOM identifies patient physiological response to cardiac resynchronization treatment.
This is a single-centre, prospective, cohort study on 50 consecutive adult patients with heart failure who are referred for CRT device treatment. The study is being conducted at University Hospital of Wales, which is a tertiary heart failure referral centre. We will perform heart scanning (echocardiography) and compare this with USCOM assessment of 21 physiological parameters at baseline and at 90 days after device implantation. We will also study heart tracings (electrocardiograms), and functional assessments of symptoms and wellbeing using the six-minute walk test (6MWT) and a patient quality of life questionnaire (MLHFQ).REC name
London - Dulwich Research Ethics Committee
REC reference
17/LO/1882
Date of REC Opinion
16 Nov 2017
REC opinion
Further Information Favourable Opinion